We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$8.56M
Cap. Flow
-$3.54M
Cap. Flow %
-2.81%
Top 10 Hldgs %
94.04%
Holding
17
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$2.59M
2
SENS icon
Senseonics Holdings Inc
SENS
+$920K
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$21.7K

Sector Composition

Rank Sector Weight
1 Healthcare 94.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.73B
$39M 31.01%
2,444,809
-157,005
-6% -$2.59M
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$31.3M 24.89%
1,300,432
-981
-0.1% -$21.7K
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$21.3M 16.97%
219,901
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$9.22M 7.33%
1,600,000
– –
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.43M 2.73%
925,000
– –
IMDZ
6
DELISTED
Immune Design Corp.
IMDZ
$3.4M 2.71%
352,300
– –
TARA icon
7
Protara Therapeutics
TARA
$220M
$3.03M 2.41%
50,447
– –
CHMA
8
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.91M 2.32%
2,080,595
– –
CLLS
9
Cellectis
CLLS
$277M
$2.57M 2.04%
100,000
– –
DERM
10
DELISTED
Dermira, Inc.
DERM
$2.04M 1.62%
70,000
– –
EVAR
11
DELISTED
Lombard Medical, Inc.
EVAR
$1.81M 1.44%
3,473,452
– –
OCGN icon
12
Ocugen
OCGN
$416M
$1.58M 1.26%
14,815
– –
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.54M 1.23%
252,129
– –
INNL
14
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.22M 0.97%
537,235
– –
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
$1.13M 0.9%
250,000
– –
NOVN
16
DELISTED
Novan, Inc. Common Stock
NOVN
$215K 0.17%
5,337
– –
SENS icon
17
Senseonics Holdings Inc
SENS
$263M
– –
-25,844
Closed -$920K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2017 Portfolio in Review

As of Q2 2017, Abingworth held 17 positions worth $126M, down 6.4% from $134M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Abingworth's Q2 2017 filing shows 2 reduced and 1 closed positions. The largest sale was CRISPR Therapeutics, an estimated $2.59M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier.

  • Abingworth's biggest Q2 2017 reduction was CRISPR Therapeutics, cutting an estimated $2.59M.
  • Abingworth fully exited Senseonics Holdings Inc in Q2 2017, selling an estimated $920K.
  • Abingworth's ten largest holdings make up 94% of its $126M portfolio in Q2 2017.
  • Abingworth opened 0 new positions and closed 1 in Q2 2017.
  • Abingworth's portfolio value fell 6.4% quarter-over-quarter to $126M.

Based on Abingworth's 13F filing for Q2 2017, filed 14 Aug 2017.